Blog examines U.S. government's stance on future of AMFm

In the Center for Global Development's (CGD) "Global Health Policy" blog, Victoria Fan, a CGD research fellow, and Rachel Silverman, a research assistant for the CGD global health team, examine the potential reasons behind "the U.S. government's apparent lack of support, particularly its legislated 'opt-in' stance," on the Affordable Medicines Facility for Malaria (AMFm), and they note "AMFm's continued survival [is] all but impossible without an explicit endorsement by the U.S. Global Malaria Coordinator (currently Rear Admiral Tim Ziemer) who leads the U.S. President's Malaria Initiative (PMI)." Fan and Silverman continue, "The question that the U.S. government must face is not only whether there is compelling evidence of AMFm's success, but whether the termination of AMFm would be more disastrous than AMFm's continuation, albeit modified." They conclude, "Most importantly, personal biases and potential conflicts of interest need to be put aside -- if not made transparent -- for the benefit of evidence-based debate and decision-making and for the many people and children that would have died without AMFm" (9/21).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Artemisinin resistance detected in children with severe malaria in Uganda